Xenon Pharmaceuticals (XENE) News Today $39.73 +0.35 (+0.89%) Closing price 04:00 PM EasternExtended Trading$39.73 0.00 (0.00%) As of 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025February 20 at 4:21 PM | financialpost.comXenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025February 20 at 4:21 PM | financialpost.comXenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025February 20 at 4:01 PM | globenewswire.comInvestors Purchase High Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE)Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the target of some unusual options trading on Wednesday. Stock investors purchased 4,063 put options on the stock. This represents an increase of 2,362% compared to the typical volume of 165 put options.February 20 at 2:41 AM | marketbeat.comTimesSquare Capital Management LLC Has $33.28 Million Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)TimesSquare Capital Management LLC lifted its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 9.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 848,850 shares of the biopharmaceutical compFebruary 19 at 6:37 AM | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives $56.00 Average PT from BrokeragesFebruary 15, 2025 | americanbankingnews.comXenon Pharmaceuticals (NASDAQ:XENE) Now Covered by Analysts at Deutsche Bank AktiengesellschaftFebruary 14, 2025 | americanbankingnews.comDeutsche Bank Initiates Coverage of Xenon Pharmaceuticals (XENE) with Buy RecommendationFebruary 12, 2025 | msn.comDeutsche Bank sets Xenon stock Buy rating, $67 price targetFebruary 11, 2025 | msn.comXenon Pharmaceuticals initiated with a Buy at Deutsche BankFebruary 11, 2025 | markets.businessinsider.comXenon Pharmaceuticals (NASDAQ:XENE) Coverage Initiated by Analysts at Deutsche Bank AktiengesellschaftDeutsche Bank Aktiengesellschaft began coverage on Xenon Pharmaceuticals in a research report on Tuesday. They set a "buy" rating and a $67.00 target price for the company.February 11, 2025 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of "Buy" by BrokeragesXenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) has been given a consensus rating of "Buy" by the eight brokerages that are covering the firm, Marketbeat reports. Seven analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the companFebruary 10, 2025 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Acquired by abrdn plcabrdn plc boosted its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 14.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 283,899 shares of the biopharmaceutical company's stock after purchasing an additionaFebruary 8, 2025 | marketbeat.comXenon Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:XENE)Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Investors bought 4,063 put options on the stock. This is an increase of 2,362% compared to the average daily volume of 165 put options.February 6, 2025 | marketbeat.comJennison Associates LLC Purchases 224,892 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Jennison Associates LLC grew its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 39.0% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 801,553 shares of the biopharmaceutical company's stock after buFebruary 5, 2025 | marketbeat.comWe're Not Very Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn RateFebruary 2, 2025 | finance.yahoo.comLeerink Partnrs Has Bearish Outlook for XENE FY2025 EarningsXenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Research analysts at Leerink Partnrs reduced their FY2025 earnings per share estimates for shares of Xenon Pharmaceuticals in a report released on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceuJanuary 31, 2025 | marketbeat.comIan Mortimer Sells 16,315 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) StockJanuary 28, 2025 | insidertrades.comXenon Pharmaceuticals CEO sells shares worth $2.21 millionJanuary 27, 2025 | msn.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) CEO Ian Mortimer Sells 16,315 SharesXenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) CEO Ian Mortimer sold 16,315 shares of Xenon Pharmaceuticals stock in a transaction on Monday, January 27th. The shares were sold at an average price of $40.50, for a total value of $660,757.50. Following the completion of the sale, the chief executive officer now directly owns 31,302 shares of the company's stock, valued at $1,267,731. This trade represents a 34.26 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.January 27, 2025 | marketbeat.comIan Mortimer Sells 22,468 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) StockXenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) CEO Ian Mortimer sold 22,468 shares of the firm's stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $40.20, for a total transaction of $903,213.60. Following the completion of the sale, the chief executive officer now owns 31,302 shares of the company's stock, valued at approximately $1,258,340.40. This trade represents a 41.79 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.January 27, 2025 | marketbeat.comWedbush Lowers Earnings Estimates for Xenon PharmaceuticalsXenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Wedbush decreased their Q1 2025 earnings per share (EPS) estimates for shares of Xenon Pharmaceuticals in a research note issued to investors on Thursday, January 23rd. Wedbush analyst L. Chico now forecasts that the biopharmaceutical compaJanuary 27, 2025 | marketbeat.comFY2029 Earnings Estimate for XENE Issued By WedbushXenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Stock analysts at Wedbush issued their FY2029 earnings per share (EPS) estimates for Xenon Pharmaceuticals in a research report issued to clients and investors on Thursday, January 23rd. Wedbush analyst L. Chico forecasts that the biopharmaJanuary 24, 2025 | marketbeat.comCantor Fitzgerald Comments on XENE FY2025 EarningsXenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 EPS estimates for Xenon Pharmaceuticals in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer anticipates that the biopharmaceutical company will posJanuary 23, 2025 | marketbeat.comXenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) saw unusually large options trading activity on Wednesday. Traders acquired 4,063 put options on the company. This is an increase of approximately 2,362% compared to the average volume of 165 put options.January 23, 2025 | marketbeat.comAssenagon Asset Management S.A. Has $9.35 Million Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Assenagon Asset Management S.A. grew its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 12.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 238,522 shares of the biopharmaceutical company's sJanuary 19, 2025 | marketbeat.comXenon Pharmaceuticals announces executive changesJanuary 17, 2025 | msn.comBarclays PLC Increases Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Barclays PLC grew its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 1,275.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 14,993 shares of the biopharmaceutical company's stock after buying an additional 13,903 shares during the peJanuary 17, 2025 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Rating of "Buy" from BrokeragesXenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) has earned a consensus recommendation of "Buy" from the eight analysts that are covering the stock, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the coJanuary 16, 2025 | marketbeat.comXenon Pharmaceuticals: 2025 Could Be Pivotal For Azetukalner's Epilepsy PotentialJanuary 16, 2025 | seekingalpha.comXenon Pharmaceuticals outlines key corporate milestone opportunities for 2025January 15, 2025 | markets.businessinsider.comXenon Outlines Key Corporate Milestone Opportunities for 2025January 13, 2025 | globenewswire.comInvestors Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the target of some unusual options trading on Wednesday. Stock investors bought 4,063 put options on the company. This is an increase of 2,362% compared to the typical volume of 165 put options.January 9, 2025 | marketbeat.comXenon to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 7, 2025 | globenewswire.comJPMorgan Chase & Co. Buys 905,129 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)JPMorgan Chase & Co. raised its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 1,263.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 976,783 shares of the biopharmaceutical company's stock afterJanuary 6, 2025 | marketbeat.comBarclays PLC Has $590,000 Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Barclays PLC boosted its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 1,275.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,993 shares of the biopharmaceutical comJanuary 2, 2025 | marketbeat.comState Street Corp Buys 32,701 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)State Street Corp raised its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 13.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 279,513 shares of the biopharmaceutical company's stock after purchasing an additioDecember 26, 2024 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Rating of "Buy" from BrokeragesShares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) have earned a consensus recommendation of "Buy" from the nine ratings firms that are covering the firm, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy recommendation and one has issued a strong buy reDecember 22, 2024 | marketbeat.comFranklin Resources Inc. Reduces Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Franklin Resources Inc. decreased its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 2.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 565,915 shares of the biopharmaceutical company's stock after sellingDecember 20, 2024 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) CFO Sherry Aulin Sells 18,709 SharesXenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) CFO Sherry Aulin sold 18,709 shares of the business's stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $41.21, for a total value of $770,997.89. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.December 19, 2024 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Shares Down 3.1% - Here's What HappenedXenon Pharmaceuticals (NASDAQ:XENE) Shares Down 3.1% - What's Next?December 19, 2024 | marketbeat.comLord Abbett & CO. LLC Has $6.85 Million Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Lord Abbett & CO. LLC trimmed its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 8.4% in the third quarter, according to its most recent filing with the SEC. The firm owned 173,985 shares of the biopharmaceutical company's stock after selling 16,048 shares during thDecember 17, 2024 | marketbeat.comPromising Efficacy and Tolerability: Douglas Tsao’s Buy Rating on Xenon Pharmaceuticals’ AzetukalnerDecember 12, 2024 | markets.businessinsider.comXenon Pharmaceuticals (NASDAQ:XENE) Given Buy Rating at HC WainwrightHC Wainwright reissued a "buy" rating and set a $53.00 price objective on shares of Xenon Pharmaceuticals in a report on Thursday.December 12, 2024 | marketbeat.comStock Traders Buy Large Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE)Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) saw some unusual options trading activity on Wednesday. Traders bought 4,063 put options on the company. This is an increase of 2,362% compared to the typical daily volume of 165 put options.December 12, 2024 | marketbeat.comPromising Phase IIb Data and Pipeline Advancements Drive Buy Rating for XenonDecember 10, 2024 | markets.businessinsider.comWellington Management Group LLP Has $151.32 Million Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Wellington Management Group LLP lifted its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 0.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,843,447 shares ofDecember 10, 2024 | marketbeat.comTwo Sigma Advisers LP Has $10.78 Million Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Two Sigma Advisers LP increased its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 31.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 273,700 shares of the biopharmaceutiDecember 10, 2024 | marketbeat.comPoint72 Asset Management L.P. Reduces Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Point72 Asset Management L.P. trimmed its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 20.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 383,290 shares of the biopharmaceuticalDecember 7, 2024 | marketbeat.comXenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024December 6, 2024 | globenewswire.com Get Xenon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter. Email Address XENE Media Mentions By Week XENE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. XENE News Sentiment▼0.670.60▲Average Medical News Sentiment XENE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. XENE Articles This Week▼74▲XENE Articles Average Week Get Xenon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Dr. Reddy's Laboratories News Vaxcyte News Sarepta Therapeutics News Qiagen News Ascendis Pharma A/S News Roivant Sciences News Revolution Medicines News Legend Biotech News BridgeBio Pharma News Axsome Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:XENE) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
